Literature DB >> 23546882

MicroRNA-144 is regulated by activator protein-1 (AP-1) and decreases expression of Alzheimer disease-related a disintegrin and metalloprotease 10 (ADAM10).

Cong Cheng1, Weiguang Li, Zheng Zhang, Shohei Yoshimura, Qinyu Hao, Chi Zhang, Zhao Wang.   

Abstract

BACKGROUND: MicroRNA (miR) dysregulation is found in Alzheimer disease (AD). A disintegrin and metalloprotease 10 (ADAM10) prevents generation of amyloid β (Aβ) and decrease AD pathology.
RESULTS: miR-144 suppresses ADAM10 expression and is up-regulated by activator protein-1.
CONCLUSION: miR-144 is a negative regulator of ADAM10 and may be involved in AD pathogenesis. SIGNIFICANCE: The first work to demonstrate the function of miRNA-144 and its regulation in the pathogenesis of AD. Amyloid β-peptide (Aβ) accumulating in the brain of Alzheimer disease (AD) patients is believed to be the main pathophysiologcal cause of the disease. Proteolytic processing of the amyloid precursor protein by α-secretase ADAM10 (a disintegrin and metalloprotease 10) protects the brain from the production of the Aβ. Meanwhile, dysregulation or aberrant expression of microRNAs (miRNAs) has been widely documented in AD patients. In this study, we demonstrated that overexpression of miR-144, which was previously reported to be increased in elderly primate brains and AD patients, significantly decreased activity of the luciferase reporter containing the ADAM10 3'-untranslated region (3'-UTR) and suppressed the ADAM10 protein level, whereas the miR-144 inhibitor led to an increase of the luciferase activity. The negative regulation caused by miR-144 was strictly dependent on the binding of the miRNA to its recognition element in the ADAM10 3'-UTR. Moreover, we also showed that activator protein-1 regulates the transcription of miR-144 and the up-regulation of miR-144 at least partially induces the suppression of the ADAM10 protein in the presence of Aβ. In addition, we found that miR-451, a miRNA processed from a single gene locus with miR-144, is also involved in the regulation of ADAM10 expression. Taken together, our data therefore demonstrate miR-144/451 is a negative regulator of the ADAM10 protein and suggest a mechanistic role for miR-144/451 in AD pathogenesis.

Entities:  

Keywords:  ADAM ADAMTS; ADAM10; Alzheimers Disease; Amyloid; Gene Regulation; MicroRNA; miR-144

Mesh:

Substances:

Year:  2013        PMID: 23546882      PMCID: PMC3650412          DOI: 10.1074/jbc.M112.381392

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  70 in total

1.  A century of cognitive decline.

Authors:  B A Yankner
Journal:  Nature       Date:  2000-03-09       Impact factor: 49.962

2.  Quantitative neuronal c-fos and c-jun expression in Alzheimer's disease.

Authors:  D L Marcus; J A Strafaci; D C Miller; S Masia; C G Thomas; J Rosman; S Hussain; M L Freedman
Journal:  Neurobiol Aging       Date:  1998 Sep-Oct       Impact factor: 4.673

3.  Amyloid-beta induces Smac release via AP-1/Bim activation in cerebral endothelial cells.

Authors:  K J Yin; J-M Lee; S D Chen; J Xu; C Y Hsu
Journal:  J Neurosci       Date:  2002-11-15       Impact factor: 6.167

4.  miR-21 promotes migration and invasion by the miR-21-PDCD4-AP-1 feedback loop in human hepatocellular carcinoma.

Authors:  Qin Zhu; Zhiming Wang; Yu Hu; Jindong Li; Xinying Li; Ledu Zhou; Yun Huang
Journal:  Oncol Rep       Date:  2012-02-09       Impact factor: 3.906

5.  MicroRNA-298 and microRNA-328 regulate expression of mouse beta-amyloid precursor protein-converting enzyme 1.

Authors:  Vincent Boissonneault; Isabelle Plante; Serge Rivest; Patrick Provost
Journal:  J Biol Chem       Date:  2008-11-05       Impact factor: 5.157

Review 6.  Targeting the JNK pathway for therapeutic benefit in CNS disease.

Authors:  Donna Bozyczko-Coyne; Michael S Saporito; Robert L Hudkins
Journal:  Curr Drug Targets CNS Neurol Disord       Date:  2002-02

7.  A microRNA-based gene dysregulation pathway in Huntington's disease.

Authors:  Rory Johnson; Chiara Zuccato; Nikolai D Belyaev; Deborah J Guest; Elena Cattaneo; Noel J Buckley
Journal:  Neurobiol Dis       Date:  2007-11-13       Impact factor: 5.996

8.  Update of the FANTOM web resource: from mammalian transcriptional landscape to its dynamic regulation.

Authors:  Hideya Kawaji; Jessica Severin; Marina Lizio; Alistair R R Forrest; Erik van Nimwegen; Michael Rehli; Kate Schroder; Katharine Irvine; Harukazu Suzuki; Piero Carninci; Yoshihide Hayashizaki; Carsten O Daub
Journal:  Nucleic Acids Res       Date:  2010-11-12       Impact factor: 16.971

9.  MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus.

Authors:  Dwi Setyowati Karolina; Arunmozhiarasi Armugam; Subramaniam Tavintharan; Michael T K Wong; Su Chi Lim; Chee Fang Sum; Kandiah Jeyaseelan
Journal:  PLoS One       Date:  2011-08-01       Impact factor: 3.240

10.  Identifying transcriptional start sites of human microRNAs based on high-throughput sequencing data.

Authors:  Chia-Hung Chien; Yi-Ming Sun; Wen-Chi Chang; Pei-Yun Chiang-Hsieh; Tzong-Yi Lee; Wei-Chih Tsai; Jorng-Tzong Horng; Ann-Ping Tsou; Hsien-Da Huang
Journal:  Nucleic Acids Res       Date:  2011-08-05       Impact factor: 16.971

View more
  39 in total

1.  Transcriptional control of PAX4-regulated miR-144/451 modulates metastasis by suppressing ADAMs expression.

Authors:  J Zhang; X Qin; Q Sun; H Guo; X Wu; F Xie; Q Xu; M Yan; J Liu; Z Han; W Chen
Journal:  Oncogene       Date:  2014-08-25       Impact factor: 9.867

2.  Glucose-based regulation of miR-451/AMPK signaling depends on the OCT1 transcription factor.

Authors:  Khairul I Ansari; Daisuke Ogawa; Arun K Rooj; Sean E Lawler; Anna M Krichevsky; Mark D Johnson; E Antonio Chiocca; Agnieszka Bronisz; Jakub Godlewski
Journal:  Cell Rep       Date:  2015-04-30       Impact factor: 9.423

Review 3.  miRNA in Macrophage Development and Function.

Authors:  Sashwati Roy
Journal:  Antioxid Redox Signal       Date:  2016-08-19       Impact factor: 8.401

4.  Regulation of ADAM10 by miR-140-5p and potential relevance for Alzheimer's disease.

Authors:  Rumana Akhter; Yvonne Shao; McKenzie Shaw; Shane Formica; Maria Khrestian; James B Leverenz; Lynn M Bekris
Journal:  Neurobiol Aging       Date:  2017-11-23       Impact factor: 4.673

Review 5.  Noncoding RNAs in Alzheimer's disease.

Authors:  M Laura Idda; Rachel Munk; Kotb Abdelmohsen; Myriam Gorospe
Journal:  Wiley Interdiscip Rev RNA       Date:  2018-01-12       Impact factor: 9.957

6.  Studies on microRNAs that are correlated with the cancer stem cells in chronic myeloid leukemia.

Authors:  Xishan Zhu; Ziying Lin; Jing Du; Xu Zhou; Lawei Yang; Gang Liu
Journal:  Mol Cell Biochem       Date:  2014-01-03       Impact factor: 3.396

7.  MicroRNA-144-3p targets relaxin/insulin-like family peptide receptor 1 (RXFP1) expression in lung fibroblasts from patients with idiopathic pulmonary fibrosis.

Authors:  Harinath Bahudhanapati; Jiangning Tan; Justin A Dutta; Stephen B Strock; John Sembrat; Diana Àlvarez; Mauricio Rojas; Benedikt Jäger; Antje Prasse; Yingze Zhang; Daniel J Kass
Journal:  J Biol Chem       Date:  2019-02-01       Impact factor: 5.157

8.  The malignancy suppression role of miR-23a by targeting the BCR/ABL oncogene in chromic myeloid leukemia.

Authors:  Z Xishan; L Xianjun; L Ziying; C Guangxin; L Gang
Journal:  Cancer Gene Ther       Date:  2014-09-12       Impact factor: 5.987

Review 9.  Early Life Stress and Epigenetics in Late-onset Alzheimer's Dementia: A Systematic Review.

Authors:  Erwin Lemche
Journal:  Curr Genomics       Date:  2018-11       Impact factor: 2.236

10.  Functional studies of miR-130a on the inhibitory pathways of apoptosis in patients with chronic myeloid leukemia.

Authors:  X Zhu; H Zhao; Z Lin; G Zhang
Journal:  Cancer Gene Ther       Date:  2015-10-23       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.